Cushing's Syndrome – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 11 PAGES: 42

More Info
									          Cushing's Syndrome – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1967IDB
                                                                                              Publication Date: April 2012




Cushing's Syndrome – Pipeline Review, H1 2012                                                 GMDHC1967IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Cushing's Syndrome – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Cushing's Syndrome Overview........................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Cushing's Syndrome .......................................................................................................... 7
Cushing's Syndrome Therapeutics under Development by Companies ............................................................................................. 9
Cushing's Syndrome Therapeutics under Investigation by Universities/Institutes ............................................................................ 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Pre-Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Cushing's Syndrome Therapeutics – Products under Development by Companies ......................................................................... 14
Cushing's Syndrome Therapeutics – Products under Investigation by Universities/Institutes .......................................................... 15
Companies Involved in Cushing's Syndrome Therapeutics Development........................................................................................ 16
    Ipsen S.A. .................................................................................................................................................................................... 16
    Novartis AG ................................................................................................................................................................................. 17
    HRA Pharma, SA......................................................................................................................................................................... 18
Cushing's Syndrome – Therapeutics Assessment ........................................................................................................................... 19
    Assessment by Monotherapy Products ....................................................................................................................................... 19
    Assessment by Route of Administration ...................................................................................................................................... 20
    Assessment by Molecule Type .................................................................................................................................................... 22
Drug Profiles..................................................................................................................................................................................... 24
    LCI699 - Drug Profile ................................................................................................................................................................... 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    Mifedren - Drug Profile ................................................................................................................................................................ 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    Bexarotene - Drug Profile ............................................................................................................................................................ 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Mifepristone - Drug Profile ........................................................................................................................................................... 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27



Cushing's Syndrome – Pipeline Review, H1 2012                                                                                                      GMDHC1967IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Cushing's Syndrome – Pipeline Review, H1 2012




         R&D Progress ......................................................................................................................................................................... 27
    Mifepristone - Drug Profile ........................................................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Inhibitors Of ACTH Receptor - Drug Profile ................................................................................................................................. 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action .......................................................................................................................................
								
To top